Actavis Settles With Medicis Over Skin Drug Generic Plans

Law360, New York (April 10, 2013, 4:45 PM EDT) -- Actavis Inc. has agreed to a settlement with Medicis Pharmaceutical Corp., ending two Delaware federal patent infringement suits over its planned generic versions of two Medicis skin disease treatments, the companies announced Wednesday.

The deal settles allegations that Actavis’ abbreviated new drug applications for generic versions of Medicis’ Ziana, an acne treatment, and Zyclara, which is used to treat actinic keratosis — a disease marked by scaly or rough patches on the skin — violated three Medicis patents.

Under the terms of the deal, Actavis will...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.